ABUS vs CB
Arbutus Biopharma Corp (ABUS) versus Chubb Ltd (CB) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Not investment advice. Open the ABUS and CB stock pages for the full models.
Not investment advice.